Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Open Access
- 17 February 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 81 (2), e32
- https://doi.org/10.1136/annrheumdis-2020-217018
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Correspondence on 'Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation’ by Braaten et alAnnals Of The Rheumatic Diseases, 2020
- Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive studyJournal for ImmunoTherapy of Cancer, 2019
- Case–non-case studies: Principle, methods, bias and interpretationTherapies, 2019
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsEuropean Journal of Cancer, 2019
- Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1Annals Of The Rheumatic Diseases, 2018
- Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy RevolutionCirculation, 2018
- Myositis as an adverse event of immune checkpoint blockade for cancer therapySeminars in Arthritis and Rheumatism, 2018
- Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort studyAnnals Of The Rheumatic Diseases, 2018
- Nivolumab-related myasthenia gravis with myositis and myocarditis in JapanNeurology, 2017
- An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical StudiesDrug Safety, 2015